Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial
Abstract Background Treatment options for patients with advanced hepatocellular carcinoma (HCC) are often limited.In most cases, they are not amenable to local therapies including surgery or radiofrequency ablation.The multi-kinase inhibitor sorafenib has shown to increase overall survival in this patient group for about 3 months.Radiation therapy